Literature DB >> 11955599

Recognition of immunoglobulins by Fcgamma receptors.

Sergei Radaev1, Peter Sun.   

Abstract

Fc receptors mediate antibody dependent inflammatory response and cytotoxicity as well as certain autoimmune dysfunctions. Fcgamma receptors interact with IgG antibodies by binding the Fc portion of the antibody in asymmetric fashion creating a 1:1 receptor-ligand stoichiometry. Regions of the C-terminal domain of Fc receptors including the BC, C'E, FG loops, and the C' beta-strand interact with immunoglobulins. The lower hinge region of the antibody contributes most of the binding to the low affinity Fcgamma receptors. Carbohydrates attached to the conserved glycosylation site on Fc portion of an antibody are critical to the recognition of immunoglobulins by the low affinity Fcgamma receptor. They are likely to function as a substitution for the hydrophobic core to preserve an optimal lower hinge conformation for the receptor binding. Subtype specificities of FcgammaRIII receptor probably are determined by the length of the lower hinge regions of immunoglobulins, but not their amino acid composition as revealed by the binding study of the lower hinge peptides. These studies also paved a new way for designing of novel therapeutic compounds in fighting autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955599     DOI: 10.1016/s0161-5890(02)00036-6

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  45 in total

Review 1.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

2.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

3.  Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.

Authors:  Yin Luo; Zhaojiang Lu; Stephen W Raso; Clifford Entrican; Bruce Tangarone
Journal:  MAbs       Date:  2009-09-24       Impact factor: 5.857

4.  Post-translational modifications differentially affect IgG1 conformation and receptor binding.

Authors:  Damian Houde; Yucai Peng; Steven A Berkowitz; John R Engen
Journal:  Mol Cell Proteomics       Date:  2010-01-26       Impact factor: 5.911

5.  The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2015-02-06       Impact factor: 5.157

6.  Structure of a Therapeutic Full-Length Anti-NPRA IgG4 Antibody: Dissecting Conformational Diversity.

Authors:  Michaela Blech; Stefan Hörer; Alexander B Kuhn; Sebastian Kube; Hendrik Göddeke; Hans Kiefer; Yuguo Zang; Yannic Alber; Stefan M Kast; Martin Westermann; Mark D Tully; Lars V Schäfer; Patrick Garidel
Journal:  Biophys J       Date:  2019-04-05       Impact factor: 4.033

7.  Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.

Authors:  Dennis R Goulet; Adam Zwolak; James A Williams; Mark L Chiu; William M Atkins
Journal:  Proteins       Date:  2019-11-20

8.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

9.  Revisiting the role of glycosylation in the structure of human IgG Fc.

Authors:  M Jack Borrok; Sang Taek Jung; Tae Hyun Kang; Arthur F Monzingo; George Georgiou
Journal:  ACS Chem Biol       Date:  2012-07-10       Impact factor: 5.100

10.  Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.

Authors:  Giovanna Scapin; Xiaoyu Yang; Winifred W Prosise; Mark McCoy; Paul Reichert; Jennifer M Johnston; Ramesh S Kashi; Corey Strickland
Journal:  Nat Struct Mol Biol       Date:  2015-11-23       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.